Immunohistochemistry study of EGFR expression in head and neck squamous cell carcinoma;Estudio por inmunohistoquímica de la expresión de EGFR en carcinoma de células escamosas de cabeza y cuello

Acta Otorrinolaringologica Espanola

Volumn 56, Issue 4, 2005, Pages 143-146

  Altuna Mariezkurrena, X ^a   Algaba Guimera J ^a   Wang Rodriguez J ^b   Weisman, R ^c   Ongkeko, W ^c  

^a HOSPITAL DONOSTIA   (Spain)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

EGFR; Head and neck squamous cell carcinoma; Immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; BIOSYNTHESIS; HEAD AND NECK TUMOR; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33644809170     PISSN: 00016519     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0001-6519(05)78589-7     Document Type: Article

References (21)

1. Vokes EE, Weichselbaum RR, Lippman SM, Honk WK. Head and Neck Cancer. N Engl J Med 1993;328:184-94.
2. Adjuvant chemotherapy for advanced head and neck squamous cell carcinoma. Final report of the Head and Neck Contracts Program. Cancer 1987;60:301-11.
3. TNM classification of malignant tumours. En: Sobin LH, Wittewkind C, eds. (International Union Against Cancer), 5th ed. New York: Willey-Liss, 1997.
4. Overgaard J, Sorensen SB, Stausbol-Gron B, Hoyer M, Alsner J. TP53 mutation is an independent prognostic marker for poor outcome of radiotherapy in squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1998;42:43.
5. Grandis JR, Melhem MF, Gooding WE. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824-32.
6. Pignataro L, Pruneri G, Carboni N, Capaccio P, Cesana BM, Neri A, et al. Clinical relevance of cyclin D1 protein overexpression in laryngeal squamous cell carcinoma. J Clin Oncol 1998;16:3069-77
7. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;28(suppl 16):67-79.
8. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 1995;267:1782-8.
9. Ford AC, Grandis JR. Targeting EGFR in HNSCC. Head and Neck 2003;1:67-73.
10. Quon H, Liu FF, Cummings BJ. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head and Neck 2001;2:147-59.
11. Okano J, Gaslightwala I, Birnbaum MJ, Rustgi AK, Nakagawa H. Akt/PKB isoforms are differentially regulated by EGF stimulation. J Biol Chem 2000; 275:30934-42.
12. Grandis JR, Tewardy DJ. Elevated levels of TGF-α and EGFR messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53:3579-84
13. Grandis JR, Tewardy DJ. TGF-α and EGFR in head and neck cancer. J Cell Biochem Suppl 1993;17F:188-91.
14. Irish JC, Bernstein A. Oncogenes in head and neck cancer. Laryngoscope 1993;103:42-52.
15. Maurizi M, Scambia G, Benedetti Panici P, Ferrandina G, Almadori G, Paludetti G, et al. EGFR expression in primary laryngeal cancer: correlation with clinico-pathological features and prognostic significance. Int J Cancer 1992;52:862-6.
16. Dassonville O, Formento JL, Francoual M, Ramaioli A, Santini J, Schneider M, et al. Expression of EGFR and survival in upper aerodigestive tract cancer. J Clin Oncol 1993;11:1873-8.
17. Wen QH, Miwa T, Yoshizaki T, Nagayama I, Furukawa M, Nishijima H. Prognostic value of EGFR and TGF-α in early laryngeal cancer treated with radiotherapy. Laryngoscope 1996;106:884-8.
18. Miyaguchi M, Olofsson J, Hellquist HB. Expresión of EGFR in glottic carcinoma and its relation to recurrente alter radiotherapy. Clin Otolaryngol 1991;16:466-9.
19. Hoffmann T, Hafner D, Ballo H, Haas I, Bier H. Antitumor activity of anti-EGFR monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma cell lines. Anticancer Res 1997;17:4419-25.
20. Robert F, Ezequiel MP, Spencer SA. Phase I study of anti-EGFR antibody cetuximab in coombination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:3234-43.
21. Cohen E, Rosen F, Dekker A. Phase II study of ZD1839 (Iressa) in recurrent or metastatic SCCHN. Proceedings of ASCO 2002;21:95a, 377.